The Company provides teleconference and webcast details for
IRVINE, Calif.--(BUSINESS WIRE)--Oct. 2, 2018--
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative
treatments for aortic disorders, today announced that its preliminary
unaudited revenue for the third quarter ended September 30, 2018 is
expected to be in the range of $34.3 million to $34.7 million.
Also, based on current business trends, the Company raised the low end
of its fiscal 2018 revenue guidance to $150 million. It now anticipates
2018 revenue to be in the range of $150 million to $155 million,
compared to the previous range of $145 million to $155 million.
Teleconference and Webcast Details
The Company will host a meeting for financial analysts and investment
professionals today at The London Hotel NYC, 151 W. 54th St., New York,
NY 10019. For those unable to attend in person, a live teleconference
and webcast of the presentations will begin at 4:15 p.m. ET.
To participate in the teleconference, dial 844-242-1698 (domestic) or
512-772-3064 (international) and refer to the passcode 5966388.
A live webcast of the presentations will be available on the “Investors”
section of the Company’s website at www.endologix.com.
Following the event, a replay of the presentation and the associated
materials will be available on the same site.
A recording of the teleconference will also be available from 7:00 p.m.
ET on Tuesday, October 2, 2018, until 11:59 p.m. ET on Tuesday, October
9, 2018. To hear this recording, dial 855-859-2056 (domestic) or
404-537-3406 (international) and enter the passcode 5966388.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments
for aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it continues
to enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the United
States. For more information, visit www.endologix.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can generally be identified by the use of
words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,”
“estimate,” “forecast,” “goal,” “project,” "continue," "outlook,"
“guidance,” "future,” and other words with similar meanings.
Forward-looking statements used in this press release relate to, among
other things, Endologix’s preliminary revenue for the third quarter
ended September 30, 2018 and projected revenue for 2018. The
forward-looking statements made in this press release are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from those anticipated or projected in the
forward-looking statements. For example, the Company’s preliminary
revenue for the quarter ended September 30, 2018 has been disclosed
based on information currently available to management, has not been
subject to any review procedures by our independent registered public
accounting firm, and are subject to adjustment based on final internal
and external review and audit. In addition, the Company’s ability to
achieve its projected revenue for 2018 will be impacted by numerous
factors, including: continued market acceptance of Endologix's products;
the success of Endologix’s restructuring and strategic initiatives; the
success of clinical trials relating to Endologix’s products; Endologix’s
product research and development efforts; uncertainty in the process of
obtaining and maintaining regulatory approval for Endologix's products;
Endologix’s ability to protect its intellectual property rights and
proprietary technologies; and other economic, business, competitive and
regulatory factors. Please refer to Endologix's filings with the
Securities and Exchange Commission, including its Annual Report on Form
10-K for the year ended December 31, 2017, and its Quarterly Reports on
Form 10-Q for the quarters ended March 31, 2018 and June 30, 2018, for
more detailed information regarding these risks and uncertainties, as
well as other factors that may cause actual results to differ materially
from those expressed or implied by the forward-looking statements.
Readers are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this press release.
Endologix undertakes no obligation to update or review any forward-
looking statements in this press release to reflect new information,
events or circumstances after the date they are made, or to reflect the
occurrence of unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181002005943/en/
Source: Endologix, Inc.
Vaseem Mahboob, CFO